Evaluating the role of corticosteroid pulse therapy in patients with secondary progressive multiple sclerosis receiving mitoxantrone : a double blind randomized controlled clinical trial
Background: Multiple sclerosis (MS) is a central nervous system disorder with periods of recurrence and recovery. Mitoxantrone has been approved for secondary progressive MS (SPMS) treatment but data lacks the role of corticosteroid pulse therapy in SPMS. Objectives: To evaluate the role of corticos...
Gespeichert in:
Veröffentlicht in: | Iranian red crescent medical journal 2015-10, Vol.17 (10), p.1-6 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 6 |
---|---|
container_issue | 10 |
container_start_page | 1 |
container_title | Iranian red crescent medical journal |
container_volume | 17 |
creator | Rahimdil, Abu al-Qasim Mellat, Ali Zaynali, Ahmad |
description | Background: Multiple sclerosis (MS) is a central nervous system disorder with periods of recurrence and recovery. Mitoxantrone has been approved for secondary progressive MS (SPMS) treatment but data lacks the role of corticosteroid pulse therapy in SPMS.
Objectives: To evaluate the role of corticosteroid pulse therapy in patients with SPMS receiving mitoxantrone.
Patients and Methods: A double blind randomized controlled clinical trial was performed on 71 patients with SPMS referred to Shahid Sadoughi Hospital (Yazd, Iran) for receiving mitoxantrone in two groups. The first group (35 patients) received 20 mg mitoxantrone plus 500 mg methylprednisolone monthly for six months. The second group (36 patients) received the same dosage of mitoxantrone plus 100 CC of 5% dextrose water monthly for six months. Expanded disability status scale (EDSS), MRI plaques in both groups before and after the treatment completion and six months after the end of trial were compared together.
Results: 28 men and 43 women enrolled in the study. MRI plaques number reduced in groups significantly (2.29 vs. 2.17) without significant difference between the groups (P = 0.782). Six months after trial completion, plaques number increased in groups without significantly difference (0.72 vs. 0.77, P = 0.611). The mean value of EDSS showed significant reduction at the end of treatment in groups (0.79 and 0.53) without significant difference between the groups (P = 0.953). Six months after trial completion, EDSS increased in groups without significant difference (0.35 vs. 0.43, P = 0.624).
Conclusions: Corticosteroid pulse therapy in SPMS was effective in inflammatory process, but could not postpone or decline the neurodegenerative process and besides the imposing side effects could not result in significant improvement in EDSS and MRI plaques number in long term. |
doi_str_mv | 10.5812/ircmj.30618 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4636858</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1733193041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-b9d62fef5c520caa0ee18068447421d035c638e6bb58a5d5048d01f07ac3878d3</originalsourceid><addsrcrecordid>eNpVkctu1DAUhiNERS-wYg3yEqmaYseXeFggoapApUrdwNpy7JMZV44dbGegPBpPh9MpI7ry0Tmf_3P5m-Y1wRdckva9S2a8u6BYEPmsOWlxx1ak5p8fYsyOm9Oc7zDma9HSF81xK7gQjLOT5s_VTvtZFxc2qGwBpegBxQGZmIozMRdI0Vk0zT7DAiQ93SMX0FS_QCgZ_XRlizKYGKxO92hKcZMgZ7cDNM6-uKnqZeOrTHYZJTDgdkuz0ZX4S4eSYgD0AWlk49xXtvcuWJR0sHF0v8HWSRbI-yWsNWe0RyU57V82R4OuY716fM-a75-vvl1-Xd3cfrm-_HSzMgzTsurXVrQDDNzwFhutMUA9iZCMdawlFlNuBJUg-p5LzS3HTFpMBtxpQ2UnLT1rPu51p7kfwZq6dtJeTcmNdWMVtVNPK8Ft1SbuFBNUSC6rwLtHgRR_zJCLGl024L0OEOesSEcpWVPMSEXP96ip98oJhkMbgtXitnpwWz24Xem3_092YP_ZW4E3ewBqHgZ9IES7JrSjfwFARbfA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1733193041</pqid></control><display><type>article</type><title>Evaluating the role of corticosteroid pulse therapy in patients with secondary progressive multiple sclerosis receiving mitoxantrone : a double blind randomized controlled clinical trial</title><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Rahimdil, Abu al-Qasim ; Mellat, Ali ; Zaynali, Ahmad</creator><creatorcontrib>Rahimdil, Abu al-Qasim ; Mellat, Ali ; Zaynali, Ahmad</creatorcontrib><description>Background: Multiple sclerosis (MS) is a central nervous system disorder with periods of recurrence and recovery. Mitoxantrone has been approved for secondary progressive MS (SPMS) treatment but data lacks the role of corticosteroid pulse therapy in SPMS.
Objectives: To evaluate the role of corticosteroid pulse therapy in patients with SPMS receiving mitoxantrone.
Patients and Methods: A double blind randomized controlled clinical trial was performed on 71 patients with SPMS referred to Shahid Sadoughi Hospital (Yazd, Iran) for receiving mitoxantrone in two groups. The first group (35 patients) received 20 mg mitoxantrone plus 500 mg methylprednisolone monthly for six months. The second group (36 patients) received the same dosage of mitoxantrone plus 100 CC of 5% dextrose water monthly for six months. Expanded disability status scale (EDSS), MRI plaques in both groups before and after the treatment completion and six months after the end of trial were compared together.
Results: 28 men and 43 women enrolled in the study. MRI plaques number reduced in groups significantly (2.29 vs. 2.17) without significant difference between the groups (P = 0.782). Six months after trial completion, plaques number increased in groups without significantly difference (0.72 vs. 0.77, P = 0.611). The mean value of EDSS showed significant reduction at the end of treatment in groups (0.79 and 0.53) without significant difference between the groups (P = 0.953). Six months after trial completion, EDSS increased in groups without significant difference (0.35 vs. 0.43, P = 0.624).
Conclusions: Corticosteroid pulse therapy in SPMS was effective in inflammatory process, but could not postpone or decline the neurodegenerative process and besides the imposing side effects could not result in significant improvement in EDSS and MRI plaques number in long term.</description><identifier>ISSN: 2074-1804</identifier><identifier>EISSN: 2074-1812</identifier><identifier>DOI: 10.5812/ircmj.30618</identifier><identifier>PMID: 26566454</identifier><language>eng</language><publisher>Dubai, United Arab Emirates: Iranian Hospital</publisher><subject>Adrenocortical hormones ; Mitoxantrone ; Multiple sclerosis ; Therapeutic use ; Treatment ; هرمونات قشرة الغدة الكظرية</subject><ispartof>Iranian red crescent medical journal, 2015-10, Vol.17 (10), p.1-6</ispartof><rights>Copyright © 2015, Iranian Red Crescent Medical Journal. 2015</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-b9d62fef5c520caa0ee18068447421d035c638e6bb58a5d5048d01f07ac3878d3</citedby><cites>FETCH-LOGICAL-c403t-b9d62fef5c520caa0ee18068447421d035c638e6bb58a5d5048d01f07ac3878d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636858/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636858/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,887,27931,27932,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26566454$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rahimdil, Abu al-Qasim</creatorcontrib><creatorcontrib>Mellat, Ali</creatorcontrib><creatorcontrib>Zaynali, Ahmad</creatorcontrib><title>Evaluating the role of corticosteroid pulse therapy in patients with secondary progressive multiple sclerosis receiving mitoxantrone : a double blind randomized controlled clinical trial</title><title>Iranian red crescent medical journal</title><addtitle>Iran Red Crescent Med J</addtitle><description>Background: Multiple sclerosis (MS) is a central nervous system disorder with periods of recurrence and recovery. Mitoxantrone has been approved for secondary progressive MS (SPMS) treatment but data lacks the role of corticosteroid pulse therapy in SPMS.
Objectives: To evaluate the role of corticosteroid pulse therapy in patients with SPMS receiving mitoxantrone.
Patients and Methods: A double blind randomized controlled clinical trial was performed on 71 patients with SPMS referred to Shahid Sadoughi Hospital (Yazd, Iran) for receiving mitoxantrone in two groups. The first group (35 patients) received 20 mg mitoxantrone plus 500 mg methylprednisolone monthly for six months. The second group (36 patients) received the same dosage of mitoxantrone plus 100 CC of 5% dextrose water monthly for six months. Expanded disability status scale (EDSS), MRI plaques in both groups before and after the treatment completion and six months after the end of trial were compared together.
Results: 28 men and 43 women enrolled in the study. MRI plaques number reduced in groups significantly (2.29 vs. 2.17) without significant difference between the groups (P = 0.782). Six months after trial completion, plaques number increased in groups without significantly difference (0.72 vs. 0.77, P = 0.611). The mean value of EDSS showed significant reduction at the end of treatment in groups (0.79 and 0.53) without significant difference between the groups (P = 0.953). Six months after trial completion, EDSS increased in groups without significant difference (0.35 vs. 0.43, P = 0.624).
Conclusions: Corticosteroid pulse therapy in SPMS was effective in inflammatory process, but could not postpone or decline the neurodegenerative process and besides the imposing side effects could not result in significant improvement in EDSS and MRI plaques number in long term.</description><subject>Adrenocortical hormones</subject><subject>Mitoxantrone</subject><subject>Multiple sclerosis</subject><subject>Therapeutic use</subject><subject>Treatment</subject><subject>هرمونات قشرة الغدة الكظرية</subject><issn>2074-1804</issn><issn>2074-1812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpVkctu1DAUhiNERS-wYg3yEqmaYseXeFggoapApUrdwNpy7JMZV44dbGegPBpPh9MpI7ry0Tmf_3P5m-Y1wRdckva9S2a8u6BYEPmsOWlxx1ak5p8fYsyOm9Oc7zDma9HSF81xK7gQjLOT5s_VTvtZFxc2qGwBpegBxQGZmIozMRdI0Vk0zT7DAiQ93SMX0FS_QCgZ_XRlizKYGKxO92hKcZMgZ7cDNM6-uKnqZeOrTHYZJTDgdkuz0ZX4S4eSYgD0AWlk49xXtvcuWJR0sHF0v8HWSRbI-yWsNWe0RyU57V82R4OuY716fM-a75-vvl1-Xd3cfrm-_HSzMgzTsurXVrQDDNzwFhutMUA9iZCMdawlFlNuBJUg-p5LzS3HTFpMBtxpQ2UnLT1rPu51p7kfwZq6dtJeTcmNdWMVtVNPK8Ft1SbuFBNUSC6rwLtHgRR_zJCLGl024L0OEOesSEcpWVPMSEXP96ip98oJhkMbgtXitnpwWz24Xem3_092YP_ZW4E3ewBqHgZ9IES7JrSjfwFARbfA</recordid><startdate>20151001</startdate><enddate>20151001</enddate><creator>Rahimdil, Abu al-Qasim</creator><creator>Mellat, Ali</creator><creator>Zaynali, Ahmad</creator><general>Iranian Hospital</general><general>Kowsar</general><scope>AACQA</scope><scope>ADJCN</scope><scope>AEION</scope><scope>AHFXO</scope><scope>AHHHR</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20151001</creationdate><title>Evaluating the role of corticosteroid pulse therapy in patients with secondary progressive multiple sclerosis receiving mitoxantrone : a double blind randomized controlled clinical trial</title><author>Rahimdil, Abu al-Qasim ; Mellat, Ali ; Zaynali, Ahmad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-b9d62fef5c520caa0ee18068447421d035c638e6bb58a5d5048d01f07ac3878d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adrenocortical hormones</topic><topic>Mitoxantrone</topic><topic>Multiple sclerosis</topic><topic>Therapeutic use</topic><topic>Treatment</topic><topic>هرمونات قشرة الغدة الكظرية</topic><toplevel>online_resources</toplevel><creatorcontrib>Rahimdil, Abu al-Qasim</creatorcontrib><creatorcontrib>Mellat, Ali</creatorcontrib><creatorcontrib>Zaynali, Ahmad</creatorcontrib><collection>بنك معلومات "معرفة" لدراسات العلوم العسكرية والأمنية - e-Marefa Military & Security Database</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>مجلس التعاون الخليجي وإيران - e-Marefa The GCC-Iranian Affairs</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>دراسات الشرق الأوسط - e-Marefa Middle Eastern Studies</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Iranian red crescent medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rahimdil, Abu al-Qasim</au><au>Mellat, Ali</au><au>Zaynali, Ahmad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluating the role of corticosteroid pulse therapy in patients with secondary progressive multiple sclerosis receiving mitoxantrone : a double blind randomized controlled clinical trial</atitle><jtitle>Iranian red crescent medical journal</jtitle><addtitle>Iran Red Crescent Med J</addtitle><date>2015-10-01</date><risdate>2015</risdate><volume>17</volume><issue>10</issue><spage>1</spage><epage>6</epage><pages>1-6</pages><issn>2074-1804</issn><eissn>2074-1812</eissn><abstract>Background: Multiple sclerosis (MS) is a central nervous system disorder with periods of recurrence and recovery. Mitoxantrone has been approved for secondary progressive MS (SPMS) treatment but data lacks the role of corticosteroid pulse therapy in SPMS.
Objectives: To evaluate the role of corticosteroid pulse therapy in patients with SPMS receiving mitoxantrone.
Patients and Methods: A double blind randomized controlled clinical trial was performed on 71 patients with SPMS referred to Shahid Sadoughi Hospital (Yazd, Iran) for receiving mitoxantrone in two groups. The first group (35 patients) received 20 mg mitoxantrone plus 500 mg methylprednisolone monthly for six months. The second group (36 patients) received the same dosage of mitoxantrone plus 100 CC of 5% dextrose water monthly for six months. Expanded disability status scale (EDSS), MRI plaques in both groups before and after the treatment completion and six months after the end of trial were compared together.
Results: 28 men and 43 women enrolled in the study. MRI plaques number reduced in groups significantly (2.29 vs. 2.17) without significant difference between the groups (P = 0.782). Six months after trial completion, plaques number increased in groups without significantly difference (0.72 vs. 0.77, P = 0.611). The mean value of EDSS showed significant reduction at the end of treatment in groups (0.79 and 0.53) without significant difference between the groups (P = 0.953). Six months after trial completion, EDSS increased in groups without significant difference (0.35 vs. 0.43, P = 0.624).
Conclusions: Corticosteroid pulse therapy in SPMS was effective in inflammatory process, but could not postpone or decline the neurodegenerative process and besides the imposing side effects could not result in significant improvement in EDSS and MRI plaques number in long term.</abstract><cop>Dubai, United Arab Emirates</cop><pub>Iranian Hospital</pub><pmid>26566454</pmid><doi>10.5812/ircmj.30618</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2074-1804 |
ispartof | Iranian red crescent medical journal, 2015-10, Vol.17 (10), p.1-6 |
issn | 2074-1804 2074-1812 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4636858 |
source | PubMed Central Open Access; PubMed Central |
subjects | Adrenocortical hormones Mitoxantrone Multiple sclerosis Therapeutic use Treatment هرمونات قشرة الغدة الكظرية |
title | Evaluating the role of corticosteroid pulse therapy in patients with secondary progressive multiple sclerosis receiving mitoxantrone : a double blind randomized controlled clinical trial |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T22%3A54%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluating%20the%20role%20of%20corticosteroid%20pulse%20therapy%20in%20patients%20with%20secondary%20progressive%20multiple%20sclerosis%20receiving%20mitoxantrone%20:%20a%20double%20blind%20randomized%20controlled%20clinical%20trial&rft.jtitle=Iranian%20red%20crescent%20medical%20journal&rft.au=Rahimdil,%20Abu%20al-Qasim&rft.date=2015-10-01&rft.volume=17&rft.issue=10&rft.spage=1&rft.epage=6&rft.pages=1-6&rft.issn=2074-1804&rft.eissn=2074-1812&rft_id=info:doi/10.5812/ircmj.30618&rft_dat=%3Cproquest_pubme%3E1733193041%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1733193041&rft_id=info:pmid/26566454&rfr_iscdi=true |